CH clones, including mutant TET2, become undetectable in the peripheral blood of older adults administered the TNF blocker, HUMIRA (adalimumab). Mutant-TET2, ASXL1, TP53, CBL, PPM1D, PHF6, and STAG2 clones identified in the peripheral whole blood of patients with RA before any immunomodulatory treatment (baseline) and at 3 and 6 months after treatment with the adalimumab (V1 and V2, respectively), show a significant reduction in CH clones after treatment. (A-B) Mean ± standard error of the mean (A) and detected mutant clones (B) shown. nd, none detected; V1, visit 1; V2, visit 2.